With billions of dollars in research and development funding continuing to be invested, COVID-19 has become into a singular focus for the scientific community. However, the collective response from the scientific communities has seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies…